Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:552-561

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niemeier, A.
Right arrow Articles by Beisiegel, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niemeier, A.
Right arrow Articles by Beisiegel, U.
Related Collections
Right arrow Gene expression
Right arrow Genetically altered mice
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:552-561.)
© 1999 American Heart Association, Inc.


Original Contributions

Identification of Megalin/gp330 as a Receptor for Lipoprotein(a) In Vitro

Andreas Niemeier; Thomas Willnow; Hans Dieplinger; Christian Jacobsen; Nicolette Meyer; Jan Hilpert; Ulrike Beisiegel
Abstract—Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein of unknown physiological function. The mechanism of Lp(a) atherogenicity as well as its catabolic pathways are only incompletely understood at present. In this report, we show that the low density lipoprotein receptor (LDLR) gene family member megalin/glycoprotein (gp) 330 is capable of binding and mediating the cellular uptake and degradation of Lp(a) in vitro. A mouse embryonic yolk sac cell line with native expression of megalin/gp330 but genetically deficient in LDLR-related protein (LRP) and a control cell line carrying a double knockout for both LRP and megalin/gp330 were compared with regard to their ability to bind, internalize, and degrade dioctadecyltetramethylindocarbocyanine perchlorate (DiI)-fluorescence–labeled Lp(a) as well as equimolar amounts of 125I-labeled Lp(a) and LDL. Uptake and degradation of radiolabeled Lp(a) by the megalin/gp330-expressing cells were, on average, 2-fold higher than that of control cells. This difference could be completely abolished by addition of the receptor-associated protein, an inhibitor of ligand binding to megalin/gp330. Mutual suppression of the uptake of 125I-Lp(a) and of 125I-LDL by both unlabeled Lp(a) and LDL suggested that Lp(a) uptake is mediated at least partially by apolipoprotein B100. Binding and uptake of DiI-Lp(a) resulted in strong signals on megalin/gp330-expressing cells versus background only on control cells. In addition, we show that purified megalin/gp330, immobilized on a sensor chip, directly binds Lp(a) in a Ca2+-dependent manner with an affinity similar to that for LDL. We conclude that megalin/gp330 binds Lp(a) in vitro and is capable of mediating its cellular uptake and degradation.


Key Words: megalin • glycoprotein 330 • lipoprotein(a) • LDL • LDLR gene family




This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
G. Helguera, M. Eghbali, D. Sforza, T. Y. Minosyan, L. Toro, and E. Stefani
Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition
Physiol Genomics, January 8, 2009; 36(2): 89 - 97.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
G. Pepe, G. Chimienti, G. M. Liuzzi, B. L. Lamanuzzi, M. Nardulli, F. Lolli, E. Angles-Cano, and S. Mata
Lipoprotein(a) in the Cerebrospinal Fluid of Neurological Patients with Blood-Cerebrospinal Fluid Barrier Dysfunction
Clin. Chem., November 1, 2006; 52(11): 2043 - 2048.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
W. J. Cain, J. S. Millar, A. S. Himebauch, U. J. F. Tietge, C. Maugeais, D. Usher, and D. J. Rader
Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]
J. Lipid Res., December 1, 2005; 46(12): 2681 - 2691.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Fan, M. Challah, H. Shimoyamada, M. Shiomi, S. Marcovina, and T. Watanabe
Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a]
J. Lipid Res., June 1, 2000; 41(6): 1004 - 1012.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
B. Garner, A. H. Merry, L. Royle, D. J. Harvey, P. M. Rudd, and J. Thillet
Structural Elucidation of the N- and O-Glycans of Human Apolipoprotein(a). ROLE OF O-GLYCANS IN CONFERRING PROTEASE RESISTANCE
J. Biol. Chem., June 15, 2001; 276(25): 22200 - 22208.
[Abstract] [Full Text] [PDF]